Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
Retrieved on:
Sunday, January 9, 2022
Engineering, COVID-19, Silver, Social, Medical research, Humanities, Cell-bound complement activation products, Immunity, Therapy, Queen Mary University of London, Research, Patient, QMUL, St. Bartholomew's, Research Excellence Framework, London School of Hygiene & Tropical Medicine, Dentistry, Science, Lupus, U.S. Securities and Exchange Commission, Lipotriches exagens, Prognosis, Annual report, Security (finance), Education, TEF, Arthritis, Barts and The London School of Medicine and Dentistry, Private Securities Litigation Reform Act, Disease, CEO, SEC, RA, QMI, Woman, Precision medicine, Inflammation, Medicine, Student, RNA, Degenerative disease, Diagnosis, SAN, GLOBE, Rheumatoid arthritis, Center, Technology, Teaching Excellence Framework, Gene expression, Joint, Russell Group, Man, Pharmaceutical industry, Medical imaging, Rheumatology
The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.
Key Points:
- The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.
- RA patients often try multiple therapies empirically before they find one that lowers their disease activity.
- There are currently no reliable assays for predicting positive patient response prior to the selection of commonly prescribed biological therapeutic agents.
- Queen Mary University of London is a world-leading research-intensive university with over 28,000 students representing more than 160 nationalities.